Drug
Orforglipron clinical trials
Also written LY3502970.
Keep track of what changes. Save the orforglipron studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
51 studies that test it; most in 2023 (13)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 5 |
| 2022 | 4 |
| 2023 | 13 |
| 2024 | 10 |
| 2025 | 11 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
- Obesity
- 16
Who runs them
Industry 49 · Other 2
Eli Lilly and Company (49) · Massachusetts General Hospital (2)
Often tested with
Tested in the same studies.
Carbamazepine (1) · Clarithromycin (1) · Cyclosporine (1) · Quinidine (1) · Simvastatin (1) · Rosuvastatin (1) · Acetaminophen (1) · Midazolam (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses orforglipron is read from its arms, and is right about nine times in ten.
Testing it · 51
- A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 DiabetesRecruitingPhase 3Eli Lilly and CompanyNCT07668336Written as Orforglipron
- A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health ProblemsNot yet recruitingPhase 3Eli Lilly and CompanyNCT07790861Written as Orforglipron
- A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan FastingRecruitingPhase 3Eli Lilly and CompanyNCT07613307Written as Orforglipron
- A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)RecruitingPhase 3Eli Lilly and CompanyNCT07241390Written as Orforglipron
- A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or OverweightRecruitingPhase 3Eli Lilly and CompanyNCT07202884Written as Orforglipron
- Efficacy and Safety of Orforglipron in Participants With Peripheral Artery DiseaseRecruitingPhase 3Eli Lilly and CompanyNCT07223593Written as Orforglipron
- A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 ObesityRecruitingPhase 3Eli Lilly and CompanyNCT07794579Written as Orforglipron
- A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)RecruitingPhase 3Eli Lilly and CompanyNCT06672549Written as Orforglipron
- PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic ResponsesNot yet recruitingPhase 4Massachusetts General HospitalNCT07739537Written as Orforglipron
- A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related ComorbiditiesRecruitingPhase 3Eli Lilly and CompanyNCT06672939Written as Orforglipron
- Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy DiscontinuationNot yet recruitingPhase 4Massachusetts General HospitalNCT07729332Written as Orforglipron
- A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With MetforminCompletedPhase 3Eli Lilly and CompanyNCT06192108Written as Orforglipron
- A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the KneeActive, not recruitingPhase 3Eli Lilly and CompanyNCT07153471Written as Orforglipron
- A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 InhibitorCompletedPhase 3Eli Lilly and CompanyNCT06109311Written as Orforglipron
- A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With MetforminCompletedPhase 3Eli Lilly and CompanyNCT06045221Written as Orforglipron
- A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or OverweightCompletedPhase 3Eli Lilly and CompanyNCT06649045Written as Orforglipron
- A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 DiabetesCompletedPhase 3Eli Lilly and CompanyNCT05872620Written as Orforglipron
- A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise AloneCompletedPhase 3Eli Lilly and CompanyNCT05971940Written as Orforglipron
- A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesActive, not recruitingPhase 3Eli Lilly and CompanyNCT05869903Written as Orforglipron
- A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 DiabetesActive, not recruitingPhase 3Eli Lilly and CompanyNCT06993792Written as Orforglipron
See all 51 studies that test orforglipron →
Given in every arm · 1 — orforglipron is usual care beside what is tested
As the comparator · 1 — what is tested is compared with orforglipron
Codes
What other systems call orforglipron · ClinicalTrials.gg INT002055
- MeSH (NLM) C000729680orforglipronConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 7ZW40D021MORFORGLIPRONConfirmed FDA, NLM, Wikidata
- Wikidata Q120491908orforglipronConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C199084OrforglipronOne source FDA
- DrugBank DB18964One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000729680 | orforglipron | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 7ZW40D021M | ORFORGLIPRON | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q120491908 | orforglipron | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C199084 | Orforglipron | One source FDA |
| DrugBank | DB18964 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.